Capmatinib and Rosuvastatin: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Rosuvastatin
Capmatinib
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Increased rosuvastatin exposure and an increased risk of myopathy and rhabdomyolysis
Interaction Deep Dive
Concomitant administration of capmatinib and rosuvastatin (a BCRP substrate) increased rosuvastatin exposure and may increase the risk of myopathy and rhabdomyolysis. If coadministration is required, do not exceed a dosage of rosuvastatin 10 mg/day. During drug interaction studies, administration of a single dose of rosuvastatin 10 mg to patients receiving capmatinib (400 mg twice daily) resulted in 2.1-fold increase in the AUC and 3-fold increase in the Cmax of rosuvastatin2. In another study, when capmatinib was coadministered with rosuvastatin, the AUC(0 to infinity) of rosuvastatin increased by 108% and Cmax increased by 204% 13.
Why it happens (mechanism)
Inhibition of BCPR-mediated efflux transport of rosuvastatin
Literature reports
2 reports — tap to read
a) During drug interaction studies, administration of a single dose of rosuvastatin 10 mg to patients receiving capmatinib (400 mg twice daily) resulted in 2.08-fold increase in the AUC and 3.04-fold increase in the Cmax of rosuvastatin 2.
b) Coadministration of capmatinib with rosuvastatin (a BCRP substrate) increased rosuvastatin AUC(0 to infinity) by 108% and increased Cmax by 204% 1. Compared with rosuvastatin alone, the rosuvastatin geometric mean ratio for AUC(infinity) was 2.08 (90% CI, 1.56 to 2.76), AUC(last) was 2.03 (90% CI, 1.61 to 2.56), and Cmax was 3.04 (90% CI, 2.36 to 3.92) following coadministration of capmatinib and rosuvastatin in a small prospective single-sequence study in adult patients with MET-dysregulated advanced solid tumors refractory to currently available therapies (N=32); t(1/2) was not affected. Capmatinib 400 mg twice daily for 12 days was coadministered with a single dose of digoxin 0.25 mg and rosuvastatin 10 mg on day 12 3.
Common questions
Can I take Capmatinib and Rosuvastatin together?
Increased rosuvastatin exposure and an increased risk of myopathy and rhabdomyolysis Always confirm with your pharmacist or prescriber before making any change.
How serious is the Capmatinib and Rosuvastatin interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Capmatinib or Rosuvastatin need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (3)
- Product Information: TABRECTA(TM) oral tablets, capmatinib oral tablets. Novartis Pharmaceuticals Corporation (per FDA), East Hanover, NJ, 2020. DailyMed
- Product Information: CRESTOR(R) oral tablets, rosuvastatin calcium oral tablets. AstraZeneca Pharmaceuticals LP (per FDA), Wilmington, DE, 2023. DailyMed
- Grande E, Giovannini M, Marriere E, et al: Effect of capmatinib on the pharmacokinetics of digoxin and rosuvastatin administered as a 2-drug cocktail in patients with MET-dysregulated advanced solid tumours: a phase I, multicentre, open-label, single-sequence drug-drug interaction study. Br J Clin Pharmacol 2021; 87(7):2867-2878.
Keep reading about Rosuvastatin
Keep reading about Capmatinib
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist